Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesChetan Bettegowda, Jon Weingart, Mark Sausen et al.|Science Translational Medicine|2014Cited by 5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Livio Trusolino et al.|The Lancet Oncology|2016Cited by 1k
Toward understanding and exploiting tumor heterogeneityAsh A. Alizadeh, Jessica Zucman‐Rossi, Victoria Aranda et al.|Nature Medicine|2015Cited by 770
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Ignaty Leshchiner et al.|Nature Medicine|2019Cited by 521
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous LeukemiaMohamed Bentires‐Alj, Benjamin G. Neel, J. Guillermo Paez et al.|Cancer Research|2004Cited by 512